精优药业年报2026

2026ANNUAL REPORT 110120122124126128252Independent Auditor’s ReportConsolidated Statement of Profit or Loss andOther Comprehensive IncomeConsolidated Statement of Financial PositionConsolidated Statement of Changes in EquityConsolidated Statement of Cash FlowsNotes to the Consolidated Financial StatementsFive Years’ Financial Summary Corporate InformationChairman’s StatementManagement Discussion and AnalysisDirectors and Senior Management ProfileCorporate Governance ReportEnvironmental, Social and Governance ReportReport of the Directors02040729356093 CORPORATE INFORMATION公司資料 董事會 BOARD OF DIRECTORS Executive Directors Dr. XIE Yi(Chairman)Dr. GUO Yi(Chief Executive Officer)Mr. CHENG Yong(Deputy Chief Executive Officer)Dr. LOU YiMs. WONG Sau Kuen Independent Non-executive Directors Ms. JIN SongDr. ZENG LiMs. YANG Xiaorong 審核委員會 AUDIT COMMITTEE Ms. JIN Song(Chairman)Dr. ZENG LiMs. YANG Xiaorong 薪酬委員會 REMUNERATION COMMITTEE Ms. JIN Song(Chairman)Dr. ZENG LiMs. YANG XiaorongDr. XIE Yi 提名委員會 NOMINATION COMMITTEE Dr. XIE Yi(Chairman)Ms. JIN SongDr. ZENG LiMs. YANG Xiaorong 公司秘書 COMPANY SECRETARYMs. WONG Sau Kuen 香港法律顧問• HONG KONG LEGAL ADVISERS Chiu & Partners Solicitors 獨立核數師 INDEPENDENT AUDITOR ZSZH (HK) Fuson CPA Limited(formerly known as SFAI (HK) CPA Limited)Certified Public Accountants CORPORATE INFORMATION (CONTINUED)公司資料（續） 註冊辦事處 REGISTERED OFFICE Clarendon House2 Church StreetHamilton HM 11Bermuda Clarendon House2 Church StreetHamilton HM 11Bermuda 總辦事處及香港主要營業地點 HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS IN HONG KONG 979222206–08 Suites 2206–08, 22/FFWD Tower, Taikoo Place979 King’s RoadQuarry BayHong Kong PRINCIPAL BANKERS 主要往來銀行 Industrial and Commercial Bank of China (Asia) LimitedThe Bank of East Asia, Limited 股份過戶登記總處 PRINCIPAL SHARE REGISTRAR ANDTRANSFER OFFICE Conyers Corporate Services (Bermuda) LimitedClarendon House, 2 Church StreetHamilton HM 11Bermuda Conyers Corporate Services (Bermuda) LimitedClarendon House, 2 Church StreetHamilton HM 11Bermuda 香港股份過戶登記分處 HONG KONG BRANCH SHARE REGISTRARAND TRANSFER OFFICE 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 網站http://www.extrawell.com.hk WEBSITE http://www.extrawell.com.hk 股份代號 STOCK CODE 00858 The Stock Exchange of Hong Kong Limited: 00858 CHAIRMAN’SSTATEMENT主席報告 Dear Shareholders:致各位股東： On behalf of the board of directors (the“Board”) of Extrawell PharmaceuticalHoldings Limited (the “Company”,together with its subsidiaries, the “Group”),I am pleased to present the annualreport of the Group for the year ended31 March 2026. CHAIRMAN’S STATEMENT (CONTINUED)主席報告（續） Persistentarmed conflicts and escalating geopolitical tensionsposesignificant challenges to global geoeconomic and supply-chain stability, contributing to ongoing global trade and economicuncertainties. The external environment remains complex and volatile. 5%5% Amid the ongoing global trade and economic uncertainties, Chinaachieveda successful conclusion of the 14th Five-Year Plan(2021–2025),with its economic strength,technological capability,and comprehensive national power leaping to a new level. China’seconomy expanded at 5% annual pace in 2025, meeting the country’starget, and has entered the first year of the 15th Five-Year Plan (2026–2030)with solid momentum, registering a 5% economic growth in the firstquarter of 2026. The outline of the 15th Five-Year Plan marks a shiftfrom the previous phase of high-speed growth toward high-qualitydevelopment at a new stage, prioritising innovation and sustainability,and making domestic demand a more prominent economic driver.Meanwhile, China’s pharmaceutical industry continues to see policyrefinements and has entered a new development phase driven bydemographicshifts,rising healthcare expenditures,and ongoingscientific innovation. Influenced by the national policies and measurestodeepen the healthcare reforms,the pharmaceutical industryregulation has become increasingly stringent. The normalisation ofthe centralised volume-based procurement, dynamic adjustments tothe national reimbursement drug list, reforms to medical insurancepayment methods and the optimisation of innovative drug reviewandapproval process,continue to drive industry transformationandupgrading while intensifying competition within the industry.Pharmaceutical enterprises are facing intense competition and variouschallenges alongside the healthcare reforms and regulatory changes.Nevertheless, the Group believes that emerging opportunities andongoing challenges revolve around the highly competitive environment. Facing the challenging market situation, the Group stays focused ondisciplined cost and expense management, ongoing improvements inproduction efficiency and sales and marketing capabilities to minimisethe impacts of pricing pressure, structural realignment and intensifiedcompetition. While the Group has a foundation of self-manufacturedpharmaceuticalproducts and its